SRRA - Sierra Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.05
-0.90 (-6.95%)
As of 10:35AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close12.95
Open12.71
Bid12.05 x 1000
Ask12.27 x 800
Day's Range12.05 - 12.71
52 Week Range8.64 - 80.40
Volume10,802
Avg. Volume72,083
Market Cap125.268M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-29.56
Earnings DateMar 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est74.00
  • Why Earnings Season Could Be Great for Sierra Oncology (SRRA)
    Zacks

    Why Earnings Season Could Be Great for Sierra Oncology (SRRA)

    Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

  • CNW Group

    Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call

    VANCOUVER , Feb. 26, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its financial results for 2019 will be released on Tuesday, March 3 prior to market open. The management team from Sierra, at 8:00 a.m. ET , will host a conference call to discuss the company's progress made in 2019 and its plans for 2020. Call registration is available through the Sierra Oncology website at www.sierraoncology.com.

  • CNW Group

    Sierra Oncology to Present at the Cowen 40th Annual Health Care Conference

    VANCOUVER , Feb. 25, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that Dr. Nick Glover , President and Chief Executive Officer, will present an overview of the company entitled "Building MOMENTUM for Patients with Myelofibrosis" at the Cowen 40th Annual Health Care Conference in Boston, Massachusetts . Sierra Oncology is a late stage drug development company focused on achieving the successful registration and commercialization of its lead product candidate, momelotinib.

  • Benzinga

    The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...

  • CNW Group

    Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead

    VANCOUVER , Feb. 6, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that the Series A convertible voting preferred stock issued in its recently completed $103.0 million financing (gross proceeds) have been fully converted into shares of common stock. In addition, Gilead Sciences, Inc. (Gilead) has been issued 725,283 shares of common stock and a warrant to purchase an equivalent amount of common stock, in consideration for meaningfully reduced royalty rates and elimination of a near term milestone in an amendment to the Asset Purchase Agreement with Gilead for momelotinib, as previously announced.

  • Sierra Oncology Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Sierra Oncology Sees Hammer Chart Pattern: Time to Buy?

    Sierra Oncology has been struggling lately, but the selling pressure may be coming to an end soon.

  • PR Newswire

    Sierra Oncology Announces Reverse Stock Split

    Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its board of directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-40. The reverse stock split will be effective today at 4:30 p.m. Eastern Time. At the market open on January 23, 2020, the Company's common stock will continue to trade on The Nasdaq Global Market under the symbol "SRRA," but will be assigned a new CUSIP number (82640U404) and will trade on a split-adjusted basis.

  • GuruFocus.com

    5 More Deep-Value Stocks for 2020

    More companies to consider for the new year that are trading at a discount to net-net working capital Continue reading...

  • Here is What Hedge Funds Think About Sierra Oncology, Inc. (SRRA)
    Insider Monkey

    Here is What Hedge Funds Think About Sierra Oncology, Inc. (SRRA)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • PR Newswire

    Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

    Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today reported new analyses of Phase 3 clinical data highlighting the anemia related benefits of momelotinib directly compared to ruxolitinib, which were presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

  • CNW Group

    Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH

    VANCOUVER , Dec. 2, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it will host an Analyst & Investor Event on Sunday, December 8 th at 7:00 am ET to discuss newly reported clinical data for momelotinib that will be presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida . The event will be led by Dr. Nick Glover , President and CEO of Sierra Oncology, and will include a presentation by renowned myelofibrosis expert, Dr. Ruben Mesa , Director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center.

  • PR Newswire

    Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors

    Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it has closed its previously announced underwritten public offering, with gross proceeds to Sierra Oncology of $103 million.

  • PR Newswire

    Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis

    VANCOUVER, Nov. 20, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it has launched the MOMENTUM clinical trial for patients with myelofibrosis. The randomized double-blind global Phase 3 trial is designed to confirm the efficacy of momelotinib on myelofibrosis symptoms, transfusion independence and splenomegaly, as compared to danazol.

  • PR Newswire

    Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference

    VANCOUVER, Nov. 14, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled "Building Momentum for Patients with Myelofibrosis" at the Jefferies 2019 London Healthcare Conference in London, United Kingdom. Sierra Oncology is a late stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Momelotinib, Sierra's lead drug candidate, is a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements, a range of meaningful anemia benefits, including eliminating or reducing the need for frequent blood transfusions, and comparable spleen control to ruxolitinib.

  • PR Newswire

    Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib

    VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it has agreed to amend its Asset Purchase Agreement with Gilead Sciences, Inc. for momelotinib upon Sierra closing a qualified financing. "These are significant amendments that meaningfully enhance the potential long-term value of momelotinib for Sierra and its stockholders.

  • PR Newswire

    Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants

    VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced the pricing of an underwritten public offering of Series A convertible preferred stock, together with Series A warrants and Series B warrants, each to purchase shares of common stock, with expected gross proceeds to Sierra Oncology of $103 million. The offering is comprised of 103,000 shares of Series A preferred stock, 312,090,000 Series A warrants to purchase up to an aggregate of 312,090,000 shares of common stock at an exercise price equal to $0.33 per underlying share of common stock, and 312,090,000 Series B warrants to purchase up to an aggregate of 102,989,700 shares of common stock at an exercise price equal to $0.33 per underlying share of common stock.